Molecule
Cetirizine is a histamine-1 receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis. It is available as oral solution, injection and powder for ophthalmic solution for intravenous use. MedsAcross supplies Cetirizine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis. ZERVIATE ® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.
Source: US FDA prescribing information
ZERVIATE ®, an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors.
Source: US FDA prescribing information
The recommended dosage of ZERVIATE ® is to instill one drop in each affected eye twice daily (approximately 8 hours apart). The single-use containers are to be used immediately after opening and can be used to dose both eyes. Discard the single-use container and any remaining contents after administration. The single-use containers should be stored in the original foil pouch until ready to use. The recommended dose is one drop in each affected eye twice daily.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Contamination of Tip and Solution. To prevent contaminating the dropper tip and solution, advise patients not to touch the eyelids or surrounding areas with the tip of the single-use container.
Source: US FDA prescribing information
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates in practice. In seven clinical trials, patients with allergic conjunctivitis or those at a risk of developing allergic conjunctivitis received one drop of either cetirizine (N=511) or vehicle (N=329) in one or both eyes. The most commonly reported adverse reactions occurred in approximately 1–7% of patients treated with either ZERVIATE ® or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced. The most common adverse reactions (1–7%) were ocular hyperemia, instillation site pain, and visual acuity reduced.
Source: US FDA prescribing information
Store at 15°C to 25°C (59°F to 77°F). Single-use containers should be stored in the original foil pouch.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Cetirizine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cetirizine 1 mg/mL oral solutionOral Cold chainGeneric name | — | US FDA | Available on request |
| Quzyttir 10 mg/1 mL injectionIntravenous | Esteve Pharmaceuticals | US FDA | Available on request |
| Zerviate 2.4 mg/mL powder for ophthalmic solutionOphthalmic | Harrow Eye | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 8 December 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Cetirizine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Cetirizine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Cetirizine, including Quzyttir, Zerviate.
Yes. The US FDA first approved Cetirizine on 8 December 1995, according to Drugs@FDA.
At least one listed presentation of Cetirizine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Cetirizine is classified under ATC code R06AE07 (Cetirizine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.